Savara Pharmaceuticals is dedicated to the development of inhaled antibiotics to treat chronic and life-threatening pulmonary infections. Our lead candidate, AeroVanc™, is the first inhaled antibiotic being developed to address the growing population of MRSA-infected cystic fibrosis patients. AeroVanc pairs a clinically proven molecule and a known device, and can achieve registration following a clear regulatory track. In Phase I trials, AeroVanc was well tolerated and demonstrated an excellent pharmacokinetic profile in healthy subjects and cystic fibrosis patients. was recently granted orphan drug status, which along with Savara’s patent estate, provides strong market exclusivity.

We are interested in establishing development and commercialization partners for our programs. If interested, please contact Taneli Jouhikainen at .

Partner Login

Email: Password: